Welcome, Guest. Please login or register.
June 23, 2024, 06:49:49 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 117
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 73
Total: 73


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Warns of Rare Serious Liver Injury From Certain Hep C Meds  (Read 7058 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
FDA Warns of Rare Serious Liver Injury From Certain Hep C Meds
« on: September 30, 2019, 11:33:33 am »
The Food and Drug Administration (FDA) has issued a warning of rare liver injury, including liver failure and even death in some cases, that may occur among people taking the direct-acting antiviral (DAA) regimens Mavyret (glecaprevir/pibrentasvir), Zepatier (grazoprevir/elbasvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to treat hepatitis C virus (HCV).

The advisory is based on 63 such reports, which largely involve individuals whose moderate to severe liver impairment meant that they should not have been prescribed these particular medications in the first place. Because Mavyret, Zepatier and Vosevi all contain drugs from the protease inhibitor class of DAAs, they are not indicated for use by people who have what is known as Child-Pugh B or C liver impairment.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.